| GSK1363089 |
| N-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N’-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide |
| (CAS 849217-64-7) |
 |
| Description： |
Foretinib is an experimental drug candidate for the treatment of cancer.[1] It was discovered by Exelixis and is under development by GlaxoSmithKline.[2] It is currently in Phase II clinical trials.[3] As of December 2012 no phase III trials are registered.[3]
Foretinib is an inhibitor of the kinase enzymes c-Met and vascular endothelial growth factor receptor 2 (VEGFR-2).[4]
|
| Product No. |
KT00394 |
| Product Name |
GSK1363089 |
| Synonyms |
XL 880，EXEL 2880 |
| Formal Name |
N-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N’-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide |
| CAS Number |
849217-64-7 |
| Molecular Formula |
C34H34F2N4O6 |
| Formula Weight |
632.65 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
AAL-993
KRN 633
PKC 412
SU 1498
Vatalanib (hydrochloride)
EMD 1214063
AZD9291
CO-1686 (AVL-301)
Crizotinib (PF-02341066)
|
|
